D&O

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Retrieved on: 
금요일, 8월 11, 2023
PK, Insurance, FNIH, PD, D&O, Osteoporosis, CMC, Hypoparathyroidism, Consultant, Entera, PTH, Tablet, Patient, Patent, Peptide, R, Research, Safety, Fine chemical, Pharmaceutical industry, Cryptocurrency

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023.
  • We expect to announce data from our Phase 1B study of our new generation platform in the second half of 2023.
  • Financial Results for the Six Months Ended June 30, 2023
    As of June 30, 2023, Entera had cash and cash equivalents of $9.1 million.
  • Operating expenses for the six months ended June 30, 2023 were $4.5 million, as compared to $7.1 million for the six months ended June 30, 2022.

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 8월 10, 2023
GMP, Abstract, Society, ASH, GBM, D&O, Progression-free survival, Survival, Cancer, SITC, SNO, Immunotherapy, Pakistan Society of Neuro-Oncology, Research, Brain, PFS, Glioblastoma, ASCO, Research and development, Development, Patient, DRI, TTP, Annual general meeting, Society for Immunotherapy of Cancer, R, Ovarian cancer, Safety, ORR, Deltex Medical Group, Pharmaceutical industry, Vaccine, Airline

INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023.

Key Points: 
  • INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023.
  • In addition, the Company provided an overview of recent corporate developments through August 2023.
  • The Company will be hosting an R&D Day on Thursday, October 12, 2023 in New York City, with details to follow.
  • Cash: As of June 30, 2023, the Company had cash of $17.0 million, compared to $10.9 million as of March 31, 2023.

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 8월 10, 2023
Research fellow, Insurance, Net, G&A, CHF, Research, Participation, D&O, Q&A, Biology, EDT, BST, Renewable energy, Indivior

During the first half of 2023, income increased by CHF 0.7 million to CHF 1.1 million compared to CHF 0.4 million in the first half of 2022.

Key Points: 
  • During the first half of 2023, income increased by CHF 0.7 million to CHF 1.1 million compared to CHF 0.4 million in the first half of 2022.
  • During the second quarter of 2023, income increased by CHF 0.4 million to CHF 0.6 million compared to CHF 0.2 million in the second quarter of 2022.
  • R&D expenses decreased by CHF 5.9 million to CHF 3.6 million in the first half of 2023 compared to CHF 9.5 million in the first half of 2022 and by CHF 3.9 million to CHF 1.8 million in the second quarter of 2023 compared to CHF 5.7 million in the second quarter of 2022.
  • Our net loss decreased by CHF 8.0 million to CHF 5.0 million in the first half of 2023 compared to CHF 13.0 million in the first half of 2022 and by CHF 4.5 million to CHF 2.7 million in the second quarter of 2023 compared to CHF 7.2 million in the second quarter of 2022.

Arbe Announces Q2 2023 Financial Results

Retrieved on: 
수요일, 8월 9, 2023
Insurance, D&O, Marketing, Original equipment manufacturer, Perception, RFP, RFQ, Research and development, TEL, Development, Radar, Administration, Average cost, Weifu Fangkai Cup, Growth, Entrepreneurship, Callers, Safety, Management, Video game, Research

TEL AVIV, Israel, Aug. 9, 2023 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) ("Arbe"), a global leader in perception radar solutions, today announced financial results for its second quarter ended June 30, 2023.

Key Points: 
  • TEL AVIV, Israel, Aug. 9, 2023 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) ("Arbe"), a global leader in perception radar solutions, today announced financial results for its second quarter ended June 30, 2023.
  • Revenues for Q2 2023 were $0.3 million, a decrease from $1.2 million in Q2 2022.
  • The decrease was primarily in Research and Development, from $9.5 million in Q2 2022 to $9.1 million in Q2 2023 and a decrease in General and Administrative expenses, from $2.3 million in Q2 2022 to $2.0 million in Q2 2023.
  • As a result, our operating loss in Q2 2023 was $12.6 million compared to $12.1 million in Q2 2022.

eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
화요일, 8월 8, 2023
Insurance, ER, Fulvestrant, G&A, MNK, Salk Institute for Biological Studies, Science, Patent, Patient, Investment, Artificial intelligence, Research and development, R, Therapy, Executive director, University, Champaign–Urbana metropolitan area, Research, Effector, Lung cancer, ZF, Drug discovery, ZFA, PD-L1, PR, Safety, D&O, Aes, Cancer, STRI Group, Messenger, PFS, Cell, Assistant, Expense, AbbVie, Administration, Pembrolizumab, Research fellow, Sale, ASCO, KICKSTART, Stanford University School of Medicine, FA, Breast cancer, Vaccine, Pharmaceutical industry, Cryptocurrency, Biochemistry, Genetics, NSCLC, Biology, Medicine

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • “It was another productive quarter for eFFECTOR as we made considerable progress on all fronts,” remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • Topline data are anticipated in the second half of 2023.
  • $16.2 million in gross proceeds raised from two registered direct financings, extending cash runway into second quarter of 2024. eFFECTOR completed two registered direct financings during the second quarter of 2023.
  • eFFECTOR anticipates that its current cash, cash equivalents and short-term investments will be sufficient to fund operations into the second quarter of 2024.

Hyzon Motors Inc., Announces Second Quarter 2023 Financial and Operational Results

Retrieved on: 
화요일, 8월 8, 2023
Insurance, Compass Minerals, FCEV, SG, Table, D&O, Q&A, TreeHouse Foods, Foulston, GAAP, Research, Ratio, Membrane electrode assembly, Audit committee, EBITDA, Investment, Earnout, Webcast, CFO, R, Professional Football Compensation Committee, PFG, FCS, Compensated emancipation, Hyundai ix35 FCEV, Satellite navigation device, Cryptocurrency, Rail transport, Hyzon Motors

ROCHESTER, N.Y., Aug. 8, 2023 /PRNewswire/ -- Hyzon Motors Inc. (NASDAQ: HYZN) ("Hyzon" or the "Company"), a high-power hydrogen fuel cell technology developer and global supplier of zero-emission heavy-duty fuel cell electric vehicles ("FCEVs"), today announced its second quarter 2023 financial and operational results.

Key Points: 
  • ROCHESTER, N.Y., Aug. 8, 2023 /PRNewswire/ -- Hyzon Motors Inc. (NASDAQ: HYZN) ("Hyzon" or the "Company"), a high-power hydrogen fuel cell technology developer and global supplier of zero-emission heavy-duty fuel cell electric vehicles ("FCEVs"), today announced its second quarter 2023 financial and operational results.
  • By the end of the second quarter, Hyzon had deployed seven vehicles under commercial agreements to customers in 2023; three additional vehicles were deployed subsequent to the quarter end.
  • This followed successful completion and factory acceptance testing of the initial three single-stack 200kW FCS during the first quarter of 2023.
  • The Hyzon management team will host a conference call to discuss its second quarter 2023 financial results on Tuesday, August 8, 2023, at 8:30 a.m. Eastern Time.

Zywave Expands API Capabilities, Empowers Insurance Organizations to Maximize Data-Driven Potential

Retrieved on: 
화요일, 8월 1, 2023
Cloud, Benchmark, Insurance, Zywave, D&O, Policy, API, Risk management, Organization, Philosophy, Cyber, Data, Casualty loss, Fintech, Benchmarking, Content, D, Fine chemical

MILWAUKEE, Wis., Aug. 1, 2023 /PRNewswire/ -- Zywave, an industry-leading provider of insurtech solutions, announced today the expansion of its API capabilities, which enable insurance organizations to further maximize their data-driven opportunities throughout the entire prospect-to-client journey. Through these multiple solutions, Zywave will provide users access to insightful, new data sets, empower organizations to optimize their technology workflows, and enable them to use their existing data in meaningful, new ways.

Key Points: 
  • MILWAUKEE, Wis., Aug. 1, 2023 /PRNewswire/ -- Zywave, an industry-leading provider of insurtech solutions, announced today the expansion of its API capabilities, which enable insurance organizations to further maximize their data-driven opportunities throughout the entire prospect-to-client journey.
  • Over the past few months, the insurtech provider released two new API products, including Lead Insights API, which provides access to a comprehensive database for lead generation; and Personal Lines Quoting API, a solution that brings quoting with carrier-direct pricing into an insurance organization's existing technology platform.
  • With Zywave's extensive portfolio of API solutions, its customers will increase efficiency, optimize their workflows, and drive strategic growth.
  • As API technology and API-enabled partners increasingly become key insurtech investments, Zywave will continue to lead the market with a philosophy of open architecture and a focus on strategic data partnerships.

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Retrieved on: 
월요일, 7월 31, 2023
IPR, Intensity, D&O, Clinical trial, Lead, G&A, Toxicity, Research, NSCLC, Lung cancer, IPhone XR, PRTG, Acquisition, University of California, Patient, UCSF, Investment, Nature, University, City, Merck, Pembrolizumab, Therapy, MD Anderson Cancer Center, Merck Sharp & Dohme Federal Credit Union, Safety, Prostate cancer, D, Pharmaceutical industry, Cryptocurrency, Life insurance, Taro (river)

R&D costs increased by approximately $1.4 million, or approximately 21%, from approximately $6.8 million in Fiscal 2022, to approximately $8.2 million in Fiscal 2023.

Key Points: 
  • R&D costs increased by approximately $1.4 million, or approximately 21%, from approximately $6.8 million in Fiscal 2022, to approximately $8.2 million in Fiscal 2023.
  • Additionally, the Company incurred additional R&D service costs totaling $0.4 million in Fiscal 2023.
  • G&A expenses decreased by approximately $0.4 million, or approximately 5%, from approximately $8.8 million in Fiscal 2022, to approximately $8.4 million in Fiscal 2023.
  • As of March 31, 2023, the Company had cash and cash equivalents of approximately $10.5 million and total current liabilities of approximately $1.9 million.

Woodruff Sawyer's Mid-Year Databox Report: Security Class Action Lawsuits Steady, Settlements Way UP

Retrieved on: 
화요일, 7월 25, 2023
Initial public offering, Wells Fargo, Insurance, SCA, SPAC, Security (finance), Securities Class Action, Senior, D&O, SAN, D

SAN FRANCISCO, July 25, 2023 /PRNewswire/ -- Woodruff Sawyer's 2023 Mid-Year Databox Report, tracking Securities Class Action (SCA) lawsuits, highlights an intriguing trend. Current economic conditions have dramatically slowed the pace of IPOs, SPAC IPOs, and de-SPAC activity—popular sources of litigation for the plaintiffs' bar. However, SCA filings have increased slightly in the first half of the year and settlements, clocking in at $2.1B (excluding Wells Fargo's recent $1B settlement) are the highest they have been in a decade.

Key Points: 
  • SAN FRANCISCO, July 25, 2023 /PRNewswire/ -- Woodruff Sawyer's 2023 Mid-Year Databox Report , tracking Securities Class Action (SCA) lawsuits, highlights an intriguing trend.
  • Current economic conditions have dramatically slowed the pace of IPOs, SPAC IPOs, and de-SPAC activity—popular sources of litigation for the plaintiffs' bar.
  • Excluding the $1 billion settlement by Wells Fargo & Company, the remaining top nine settlements comprised 67% of total settlement dollars ($1.4 billion).
  • With over 450 cases yet to be resolved, we anticipate that this be another expensive year for settlements.

Ivans Distribution Platform Expands to Support Cyber and More for Commercial Lines of Business

Retrieved on: 
목요일, 7월 13, 2023
Umbrella, Communication, D&O, Workers' compensation, Workforce, Professional liability insurance, Appetite, Cyber, Commercial property, Policy, Commercial general liability insurance, Businessperson, Business owner's policy, D, Insurance, Ivan Snehota, Inland marine insurance

Milwaukee, WI, July 13, 2023 (GLOBE NEWSWIRE) -- Ivans® today announced the expansion of commercial lines supported on Ivans Distribution Platform™ to rate, quote, and bind commercial policies.

Key Points: 
  • Milwaukee, WI, July 13, 2023 (GLOBE NEWSWIRE) -- Ivans® today announced the expansion of commercial lines supported on Ivans Distribution Platform™ to rate, quote, and bind commercial policies.
  • Along with Business Owner's Policy, General Liability and Workers' Compensation already live on the platform, Ivans Distribution Platform now also supports Cyber, D&O, E&O, Umbrella, Inland Marine, Professional Liability, Commercial Package, Commercial Property and Commercial Auto.
  • Ivans Distribution Platform improves the commercial lines policy lifecycle and connects to Ivans’ open platform of commercial markets to provide customers automated appetite communication and digitized submissions and quoting directly to insurers and MGAs’ systems.
  • The expanded solution paired with our Ivans Distribution Partners provides agents with streamlined, digital submission workflows to increase win rates and efficiencies around commercial lines business.